See more : Freedom Acquisition I Corp. (FACT) Income Statement Analysis – Financial Results
Complete financial analysis of Guangzhou LBP Medicine Science & Technology Co., Ltd. (688393.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guangzhou LBP Medicine Science & Technology Co., Ltd., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Micromem Technologies Inc. (MMTIF) Income Statement Analysis – Financial Results
- Koken Boring Machine Co.,Ltd. (6297.T) Income Statement Analysis – Financial Results
- Supreme Petrochem Limited (SPLPETRO.NS) Income Statement Analysis – Financial Results
- Quoin Pharmaceuticals, Ltd. (QNRX) Income Statement Analysis – Financial Results
- Liberty Northwest Bancorp, Inc. (LBNW) Income Statement Analysis – Financial Results
Guangzhou LBP Medicine Science & Technology Co., Ltd. (688393.SS)
About Guangzhou LBP Medicine Science & Technology Co., Ltd.
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China. It offers pathological diagnostic reagents and ancillary equipment, including liquid-based cytology, such as gynecological series, non-gynecological series, and equipment; fluorescence in situ hybridization products for various applications in breast, bladder, lung, cervical, prostate, and thyroid cancer; and neuroblastoma, soft tissue sarcoma, other solid tumors, prenatal screening and abortion, oligodendrocytes tumor, lymphoma, multiple myeloma, chronic myelogenous and lymphocytic leukemia, myelodysplastic syndromes, acute myeloid leukemia, and acute lymphoblastic leukemia. The company also provides immunohistochemistry products, which comprise antibodies, detection systems, repair systems, complementary products, and immunohistochemistry kit, as well as molecular genetic diagnosis products. Guangzhou LBP Medicine Science & Technology Co., Ltd. was founded in 2005 and is based in Guangzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 497.29M | 507.38M | 438.99M | 375.43M | 355.16M | 306.30M | 260.47M | 241.16M | 142.60M | 107.45M | 87.72M |
| Cost of Revenue | 161.87M | 146.75M | 96.95M | 75.96M | 57.94M | 52.17M | 43.21M | 42.75M | 46.27M | 37.43M | 30.77M |
| Gross Profit | 335.42M | 360.63M | 342.04M | 299.47M | 297.22M | 254.12M | 217.26M | 198.41M | 96.33M | 70.02M | 56.95M |
| Gross Profit Ratio | 67.45% | 71.08% | 77.92% | 79.77% | 83.69% | 82.97% | 83.41% | 82.27% | 67.55% | 65.16% | 64.93% |
| Research & Development | 62.69M | 67.39M | 45.90M | 27.73M | 21.86M | 15.59M | 15.30M | 13.25M | 10.62M | 15.98M | 0.00 |
| General & Administrative | 18.05M | 20.45M | 18.91M | 10.62M | 5.16M | 4.78M | 3.70M | 21.20M | 23.87M | 25.01M | 13.23M |
| Selling & Marketing | 182.66M | 185.97M | 179.59M | 153.56M | 161.88M | 141.81M | 122.84M | 112.57M | 31.63M | 14.33M | 14.68M |
| SG&A | 200.71M | 206.42M | 198.50M | 164.18M | 167.04M | 146.59M | 126.54M | 133.77M | 55.49M | 39.34M | 27.91M |
| Other Expenses | -12.07M | 55.21M | 30.59M | 11.82M | 20.05M | 110.17K | -571.10K | 8.29M | 3.98M | 2.39M | 4.45M |
| Operating Expenses | 319.10M | 329.02M | 275.00M | 203.73M | 208.94M | 179.43M | 157.30M | 150.03M | 57.22M | 40.40M | 29.25M |
| Cost & Expenses | 475.78M | 475.77M | 371.94M | 279.69M | 266.89M | 231.61M | 200.51M | 192.77M | 103.49M | 77.83M | 60.01M |
| Interest Income | 8.80M | 7.69M | 12.37M | 6.22M | 660.30K | 699.71K | 436.74K | 782.48K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 808.03K | 1.36M | 384.10K | 73.77K | 113.44K | 18.00K | 48.08K | 40.60K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 47.01M | 39.68M | 21.92M | 11.64M | 12.84M | 13.19M | 13.67M | 12.04M | 4.95M | 2.96M | 3.28M |
| EBITDA | 66.48M | 71.39M | 111.26M | 111.57M | 99.60M | 87.75M | 73.79M | 67.35M | 42.88M | 32.58M | 30.99M |
| EBITDA Ratio | 13.37% | 14.69% | 23.77% | 29.80% | 28.56% | 29.52% | 28.57% | 28.97% | 31.95% | 30.74% | 35.62% |
| Operating Income | 21.51M | 38.85M | 88.94M | 100.20M | 88.80M | 74.36M | 60.65M | 46.98M | 40.26M | 29.91M | 27.34M |
| Operating Income Ratio | 4.33% | 7.66% | 20.26% | 26.69% | 25.00% | 24.28% | 23.28% | 19.48% | 28.23% | 27.83% | 31.17% |
| Total Other Income/Expenses | -4.66M | -10.06M | -216.43K | -343.15K | -1.55M | 110.17K | -571.10K | 8.29M | 3.98M | 2.39M | 4.45M |
| Income Before Tax | 16.85M | 28.79M | 88.72M | 99.85M | 87.25M | 74.47M | 60.07M | 55.27M | 44.24M | 32.29M | 31.79M |
| Income Before Tax Ratio | 3.39% | 5.67% | 20.21% | 26.60% | 24.57% | 24.31% | 23.06% | 22.92% | 31.02% | 30.05% | 36.24% |
| Income Tax Expense | -4.17M | -539.23K | 13.44M | 16.23M | 14.44M | 12.05M | 10.33M | 8.41M | 5.84M | 4.56M | 4.64M |
| Net Income | 40.06M | 29.33M | 79.78M | 84.75M | 73.99M | 61.47M | 48.34M | 46.03M | 38.43M | 27.73M | 27.15M |
| Net Income Ratio | 8.06% | 5.78% | 18.17% | 22.57% | 20.83% | 20.07% | 18.56% | 19.09% | 26.95% | 25.81% | 30.95% |
| EPS | 0.43 | 0.31 | 0.85 | 0.91 | 0.79 | 0.88 | 0.69 | 0.66 | 0.55 | 0.40 | 2.71 |
| EPS Diluted | 0.42 | 0.31 | 0.85 | 0.91 | 0.79 | 0.88 | 0.69 | 0.66 | 0.55 | 0.40 | 2.71 |
| Weighted Avg Shares Out | 93.16M | 93.34M | 93.34M | 93.34M | 93.34M | 69.85M | 70.06M | 69.74M | 69.88M | 69.34M | 10.02M |
| Weighted Avg Shares Out (Dil) | 95.37M | 94.88M | 93.34M | 93.34M | 93.34M | 69.85M | 70.06M | 69.74M | 69.88M | 69.34M | 10.02M |
Source: https://incomestatements.info
Category: Stock Reports